Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
954 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,459 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00597246 | Imaging Brain Tumors With FACBC and Methionine | completed | N/A | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00979810 | Image-Guided Stereotactic Biopsy of High Grade Gliomas | completed | N/A | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis |
| completed |
| Early Phase 1 |
| 10 |
| St. Joseph's Hospital and Medical Center, PhoenixOTHER |
| 1 |
| Dec 11, 2020 |
| clinicaltrials |
| NCT01905228 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm | completed | Phase 1 | 83 | IncuronINDUSTRY | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02207010 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | completed | Early Phase 1 | 20 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01473901 | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 9, 2020 | clinicaltrials |
| NCT01934361 | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas(GBM-LIPO) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03026699 | Refining and Testing the Electronic Social Network Assessment Program (eSNAP) | completed | — | 62 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03471546 | Early Palliative Care Intervention in Malignant Glioma | completed | N/A | 12 | Duke UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | completed | Phase 1 | 12 | BiogenINDUSTRY | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) | completed | Phase 1 | 15 | Genexine, Inc.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT02159443 | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | completed | — | 76 | St. Jude Children's Research HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02193724 | Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma | completed | — | 15 | St. Jude Children's Research HospitalOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT00590954 | Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00026780 | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | completed | — | 1,720 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01467986 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma(RIST-rNB-2011) | completed | Phase 2 | 130 | University of RegensburgOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT01987830 | Bevacizumab w / Temozolomide PET & Vascular MRI For GBM | completed | N/A | 13 | Massachusetts General HospitalOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | completed | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00883688 | Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT02071056 | Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM) | completed | — | 5 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00179920 | Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma | completed | Phase 2 | 30 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02540161 | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | completed | Phase 2 | 43 | Annick DesjardinsOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00342004 | A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women | completed | — | 75,366 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2020 | clinicaltrials |
| NCT01813877 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | completed | N/A | 37 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02626364 | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | completed | Phase 2 | 11 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03687099 | Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma(GLIOBLASTOMES) | completed | — | 20 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT00342953 | Study of Health Effects of Cosmetic Breast Augmentation | completed | — | 17,424 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04429139 | Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study | completed | N/A | 8 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02911155 | Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists | completed | — | 229 | National Cancer Institute (NCI)NIH | 1 | May 5, 2020 | clinicaltrials |
| NCT02799238 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma(ALECSAT) | completed | Phase 2 | 62 | CytoVac A/SINDUSTRY | 1 | Apr 30, 2020 | clinicaltrials |
| NCT02431572 | A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | completed | N/A | 11 | Massachusetts General HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02743481 | Early Life Exposures in Agriculture | completed | — | 60,000 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Dec 17, 2020source: clinicaltrials